Contact information
Colleges
Michael Desborough
BMedSci(Hons), MBChB, MRCP, FRCPath, DPhil
Consultant Haematologist & Honorary Senior Lecturer
The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.
Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.
I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).
Key publications
-
Journal article
Desborough MJ. et al, (2017), Cochrane Database Syst Rev, 7
-
Journal article
Desborough MJR. et al, (2017), J Thromb Haemost, 15, 263 - 272
-
Journal article
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
-
Journal article
Desborough MJR. et al, (2017), Thromb Haemost, 117, 889 - 898
-
Journal article
Desborough MJR. et al, (2016), Br J Haematol, 175, 381 - 392
Recent publications
-
Journal article
Law ZK. et al, (2021), J Am Heart Assoc
-
Journal article
Hadi M. et al, (2021), Cardiovasc Intervent Radiol
-
Journal article
Mortimer J. et al, (2021), eJHaem
-
Journal article
Doyle AJ. et al, (2020), Thromb Res, 196, 454 - 456
-
Journal article
Desborough MJR. et al, (2020), BMJ Open, 10
ORCID
0000-0002-1951-5616